Final follow-up (f/u) results from RADIANT: A randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection in patients (pts) with stage IB–IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC).

Mary E.R. O'Brien; Karen Kelly; Nasser K. Altorki; Wilfried Ernst Erich Eberhardt; David R. Spigel; Lucio Crino; Chun-Ming Tsai; Joo-Hang Kim; Eun Kyung Cho; Philip C. Hoffman; Shaf Keshavjee; Sergey Orlov; Piotr Serwatowski; Joe Wang; Margaret A. Foley; Julie D. Horan; Frances A. Shepherd

doi:10.1200/jco.2015.33.15_suppl.7540

Final follow-up (f/u) results from RADIANT: A randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection in patients (pts) with stage IB–IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.7540 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 7540-7540

Author(s):

Mary E.R. O'Brien ◽

Karen Kelly ◽

Nasser K. Altorki ◽

Wilfried Ernst Erich Eberhardt ◽

David R. Spigel ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Tumor Resection ◽

Small Cell ◽

Small Cell Lung ◽

Complete Tumor Resection ◽

Phase 3 ◽

Double Blind ◽

Complete Tumor

Download Full-text

A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.7501 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 7501-7501 ◽

Cited By ~ 6

Author(s):

Karen Kelly ◽

Nasser K. Altorki ◽

Wilfried Ernst Erich Eberhardt ◽

Mary E.R. O'Brien ◽

David R. Spigel ◽

...

Keyword(s):

Lung Cancer ◽

Adjuvant Chemotherapy ◽

Small Cell Lung Cancer ◽

Tumor Resection ◽

Small Cell ◽

Small Cell Lung ◽

Complete Tumor Resection ◽

Phase 3 ◽

Double Blind ◽

Complete Tumor

Download Full-text

Faculty Opinions recommendation of Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718451079.793497341 ◽

2014 ◽

Author(s):

Laurie Carr

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Disease Progression ◽

Stage Iv ◽

Small Cell ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind

Download Full-text

PD6-3-6: A phase 3 randomized, double blind, placebo-controlled study of patients with previously untreated extensive-stage small cell lung cancer (SCLC) treated with platinum plus etoposide chemotherapy with or without darbepoetin alfa

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283344.69129.a5 ◽

2007 ◽

Vol 2 (8) ◽

pp. S433-S434 ◽

Cited By ~ 2

Author(s):

Robert Pirker ◽

Rodryg Ramlau ◽

Wolfgang Schuette ◽

Petr Zatloukal ◽

Irene Ferreira ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Darbepoetin Alfa ◽

Small Cell ◽

Controlled Study ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Extensive Stage

Download Full-text

195TiP A phase 3, randomized, double-blind study of epacadostat plus pembrolizumab vs pembrolizumab as first-line therapy for metastatic non-small cell lung cancer (mNSCLC) expressing high PD-L1 levels (ECHO-305/KEYNOTE-654)

Journal of Thoracic Oncology ◽

10.1016/s1556-0864(18)30468-4 ◽

2018 ◽

Vol 13 (4) ◽

pp. S116-S117

Author(s):

L. Paz-Ares ◽

S. Rubin ◽

Y. Zhao ◽

L. Xu ◽

A. Samkari ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Double Blind Study ◽

Small Cell Lung ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70510-2 ◽

2014 ◽

Vol 15 (1) ◽

pp. 59-68 ◽

Cited By ~ 259

Author(s):

Charles Butts ◽

Mark A Socinski ◽

Paul L Mitchell ◽

Nick Thatcher ◽

Libor Havel ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Stage Iii ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind

Download Full-text

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

The Lancet ◽

10.1016/s0140-6736(14)60845-x ◽

2014 ◽

Vol 384 (9944) ◽

pp. 665-673 ◽

Cited By ~ 593

Author(s):

Edward B Garon ◽

Tudor-Eliade Ciuleanu ◽

Oscar Arrieta ◽

Kumar Prabhash ◽

Konstantinos N Syrigos ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Disease Progression ◽

Stage Iv ◽

Small Cell ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind

Download Full-text

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70355-3 ◽

2013 ◽

Vol 14 (10) ◽

pp. 953-961 ◽

Cited By ~ 203

Author(s):

Yuankai Shi ◽

Li Zhang ◽

Xiaoqing Liu ◽

Caicun Zhou ◽

Li Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Previously Treated

Download Full-text

EGFR Mutant Subset Analysis From Archer 1009: a Randomized Double Blind Phase 3 Efficacy and Safety Study of Dacomitinib Versus Erlotinib for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Annals of Oncology ◽

10.1093/annonc/mdv050.02 ◽

2015 ◽

Vol 26 ◽

pp. i29

Author(s):

L. Paz-Ares ◽

K. O'Byrne ◽

T.S.K. Mok ◽

M. Boyer ◽

P.A. Jänne ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Safety Study ◽

Phase 3 ◽

Double Blind ◽

Egfr Mutant

Download Full-text

Fortis-M, a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Oral Talactoferrin Alfa with Best Supportive Care in Patients with Advanced Non-Small Cell Lung Cancer Following Two or More Prior Regimens- by the Fortis-M Study Group

Annals of Oncology ◽

10.1016/s0923-7534(20)34343-x ◽

2012 ◽

Vol 23 ◽

pp. ixe23 ◽

Cited By ~ 1

Author(s):

S.S. Ramalingam ◽

J. Crawford ◽

A. Chang ◽

C. Manegold ◽

R. Perez-Soler ◽

...

Keyword(s):

Lung Cancer ◽

Supportive Care ◽

Small Cell Lung Cancer ◽

Best Supportive Care ◽

Small Cell ◽

Study Group ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(11)70339-4 ◽

2012 ◽

Vol 13 (3) ◽

pp. 292-299 ◽

Cited By ~ 43

Author(s):

Chandra P Belani ◽

Thomas Brodowicz ◽

Tudor E Ciuleanu ◽

Maciej Krzakowski ◽

Sung Hyun Yang ◽

...

Keyword(s):

Quality Of Life ◽

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Maintenance Treatment ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind

Download Full-text